76
|
Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D, Gosh S, Mackey JR, Sabri S, Abdulkarim B. 1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. Cancer Res 2009; 69:8620-8. [DOI: 10.1158/0008-5472.can-09-1591] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
77
|
Palmer J, Lai R, Thomas N, Bullman J, Ali Z, Baines A, Appleby J. 701 RANDOMISED, PLACEBO‐CONTROLLED, PARALLEL‐GROUP STUDY OF THE EFFECT OF SB‐705498, A TRPV1 RECEPTOR ANTAGONIST, ON PAIN FOLLOWING THIRD MOLAR TOOTH EXTRACTION. Eur J Pain 2009. [DOI: 10.1016/s1090-3801(09)60704-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
78
|
Di Donato P, Giulini NA, Bacchi Modena A, Cicchetti G, Comitini G, Gentile G, Cristiani P, Careccia A, Esposito E, Gualdi F, Golinelli S, Bergamini E, Masellis G, Rastelli S, Gigli C, Elia A, Marchesoni D, Sticotti F, Del Frate G, Zompicchiatti C, Marino L, Costa MR, Pinto P, Dodero D, Storace A, Spinelli G, Quaranta S, Bossi CM, Ollago A, Omodei U, Vaccari M, Luerti M, Repetti F, Zandonini G, Raspagliesi F, Dolci F, Gambarino G, De Pasquale B, Polizzotti G, Borsellino G, Alpinelli P, Natale N, Colombo D, Belloni C, Viani A, Cecchini G, Vinci GW, Samaja BA, Pasinetti E, Penotti M, Ognissanti F, Pesando P, Malanetto C, Gallo M, Dolfin G, Tartaglino P, Mossotto D, Pistoni A, Tarani A, Rattazzi PD, Rossaro D, Campanella M, Arisi E, Gamper M, Salvatores D, Bocchin E, Stellin G, Meli G, Azzini V, Tirozzi F, Buoso G, Fraioli R, Marsoni V, Cetera C, Sposetti R, Candiotto E, Pignalosa R, Del Pup L, Bellati U, Angeloni C, Buonerba M, Garzarelli S, Santilli C, Mucci M, Di Nisio Q, Cappa F, Pierangeli I, Cordone A, Falasca L, Ferrante D, Serra GB, Cirese E, Todaro PA, Romanini C, Spagnuolo L, Lanzone A, Donadio C, Fabiani M, Baldaccini E, Votano S, Bellardini P, Favale W, Monti V, Bonomo A, Boninfante CE, Pietrobattista P, Massacesi L, Donini G, Del Savio F, Palombi L, Procaccioli P, Romani A, Romagnoli G, Genazzani AR, Gambacciani M, Scarselli G, Curiel P, De Leo V, Melani A, Levi D'Ancona V, Giarrè G, Di Gioia E, Ceccarelli P, Massi GB, Cosci S, Gacci G, Cascianini A, Donati Sarti C, Bircolotti S, Pupita P, Mincigrucci M, Spadafora A, Santeufemia G, Marongiu G, Lai GR, Lai R, Dessole S, D'Andrea SA, Chiantera A, Arienzo R, Pastore AR, Tamburrino A, Cardone A, Colacurci N, Izzo S, Tesauro R, Pascarella A, De Silvio MG, Di Prisco L, Lauda N, Sirimarco F, Agrimi C, Casarella G, Senatore G, Ronzini S, Ruccia G, De Carlo G, Pisaturo G, Carlomagno F, Fasolino A, Fiorillo F, Sorrentino R, Ercolano VB, Panariello S, Brun A, Tropea P, Stigliano CM, Amoroso A, Vadalà P, Coco A, Galati G, Barese G, Masciari G, Pirillo P, Gioffrè T, Mastrantonio P, Cardamone A, D'Angelo N, Valentino G, Barretta R, Ferraro G, Ferruccio C, Agostinelli D, Corrado G, Scopelliti A, Schonauer S, Trojano V, Bongiovanni F, Tinelli F, Poddi ER, Scarpello F, Colonna L, Fischetti G, Doria R, Trombetta G, Cocca EB, D'Amore A, Di Masi M, Liguori R, Dimaggio A, Laneve MR, Maolo MC, Gravina G, Nacci G, Nocera F, Lupo A, Giannola C, Graziano R, Mezzatesta M, Vegna G, Giannone G, Palumbo G, Cancellieri F, Mondo A, Cordopatri A, Carrubba M, Mazzola V, Cincotta L, D'Asta S, Bono A, Li Calsi L, Cavallaro Nigro S, Schilirò S, Repici A, Gullo D, Orlando A, Specchiale F, Papotto A, Giulia FV, Adige TA, D'Aosta V, Massacesi A, Chiantera A, Donati Sarti C, De Aloysio P, Omodei U, Ognissanti F, Campagnoli C, Penotti M, Gambacciani A, Graziottin A, Baldi C, Colacurci N, Corrado Tonti G, Parazzini F, Chatenoud L. Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional study. Climacteric 2009; 8:287-93. [PMID: 16397927 DOI: 10.1080/13697130500196866] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVE To analyze risk factors for type 2 diabetes among women attending menopause clinics in Italy for counselling about the menopause. SUBJECTS Women attending a network of first-level outpatient menopause clinics in Italy for general counselling about menopause or treatment of menopausal symptoms. METHODS Cross-sectional study with no exclusion criteria. Type 2 diabetes was defined according to National Diabetes Data Groups Indications and the fasting blood glucose at an oral glucose tolerance test within the previous year. RESULTS Out of the 44 694 considered in this analysis, 808 had a diagnosis of diabetes type 2 (1.8%). In comparison with women aged < 50 years, the multivariate odds ratios (OR) of type 2 diabetes were 1.31 (95% confidence interval (CI), 0.99-1.74) for women aged 50-52 years, 1.66 (95% CI, 1.27-2.17) at 53-56 years and 2.84 (95% CI, 2.20-3.67) in women aged > or = 57 years. Type 2 diabetes was less frequently reported in more educated women (OR high school/university vs. primary school = 0.44 (95% CI, 0.36-0.55)). Being overweight was associated with an increased risk of type 2 diabetes. In comparison with women reporting a low level of physical activity, the multivariate OR of type 2 diabetes was 0.67 (95% CI, 0.54-0.84) for women reporting regular physical activity. In comparison with premenopausal women, the multivariate OR of type 2 diabetes was 1.38 (95% CI, 1.03-1.84) in women with natural menopause. This finding was present also after allowing for the potential confounding effect of age. The multivariate OR of diabetes for users of hormonal replacement therapy was 0.58 (95% CI, 0.46-0.73). CONCLUSIONS This large cross-sectional study suggests that postmenopausal women are at higher risk of type 2 diabetes after allowance for the effect of age. Other main determinants of risk of type 2 diabetes in women around menopause were low socioeconomic status and being overweight. Diabetes was found less frequently in those taking hormone replacement therapy.
Collapse
|
79
|
Zhang CX, Yang SY, Xu MX, Sun J, Liu H, Liu JR, Liu H, Kan F, Sun J, Lai R, Zhang KY. Serratia nematodiphila sp. nov., associated symbiotically with the entomopathogenic nematode Heterorhabditidoides chongmingensis (Rhabditida: Rhabditidae). Int J Syst Evol Microbiol 2009. [DOI: 10.1099/ijs.0.003871-0] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|
80
|
Liu H, Zhou Y, Liu R, Zhang KY, Lai R. Bacillus solisalsi sp. nov., a halotolerant, alkaliphilic bacterium isolated from soil around a salt lake. Int J Syst Evol Microbiol 2009; 59:1460-4. [DOI: 10.1099/ijs.0.000653-0] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
81
|
Gelebart P, Zak Z, Anand M, Dien-Bard J, Amin HM, Lai R. Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia 2009; 23:1836-46. [DOI: 10.1038/leu.2009.100] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
82
|
Abrey LE, Correa D, Yahalom J, Raizer J, Grimm S, Lai R, Schiff D, Grant B, DeAngelis LM, Morris PG. Combination immunochemotherapy followed by reduced dose (rd) whole brain radiation therapy (WBRT) in an expanded cohort of patients with newly diagnosed primary central nervous system lymphoma (PCNSL). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2072 Background: High-dose methotrexate (M)-based chemotherapy combined with WBRT has improved survival in patients with PCNSL. However, disease recurrence and treatment-related neurotoxicity are significant problems. We conducted a prospective trial incorporating rituximab (R) and rdWBRT and previously demonstrated this was feasible. This study was extended to assess the long-term outcome of this approach in an expanded cohort. Methods: Patients were treated with R-MPV (d1 R 500mg/m2; d2 M 3.5gm/m2; vincristine 1.4mg/m2; d1–7 procarbazine 100 mg/m2/d on odd-cycles). Patients with a PR after five cycles received two additional cycles. Patients with a CR received rdWBRT (2340cGy), otherwise patients received standard WBRT (4500cGy). Patients then received two cycles of Ara-C 3gm/m2. Prospective neuropsychological evaluations were performed at baseline, before WBRT, and every 6 months thereafter. Results: From October 2002 to September 2008, 50 patients were enrolled (22 female, 28 male), median age 59.5 years (range 30–79 years). Due to neutropenia in two of the first five patients, all subsequent patients received G-CSF. 42 patients are assessable for response (4 patients died from progressive disease prior to completing the first cycle of treatment, 4 patients - treatment ongoing). 33 patients (79%) had a CR, of whom 29 received rdWBRT (3 refused, 1 died). At median follow-up of 3 years for survivors the median OS has not been reached and the estimated 2-year OS is 68%. Patients treated with rdWBRT have a median follow up of 38 months: 21 (72%) are alive with no evidence of disease, seven (24%) relapsed, and one died of unknown causes. Eight of 21 (38%) who are alive with no evidence of disease were age 60+ at diagnosis. The number of patients treated with rdWBRT alive with no evidence of disease at 3, 4, and 5 years is 12, 8, and 4 respectively. 9 patients have completed neuropsychological evaluations 24 months after rdWBRT with no significant cognitive decline detectable. Conclusions: Prolonged follow-up of an expanded cohort of patients treated with immunochemotherapy followed by rdWBRT for patients with an initial CR continues to support our initial conclusions that this approach results in excellent disease control with no observed treatment-related neurotoxicity. [Table: see text]
Collapse
|
83
|
Wang J, Zhang S, Lai R. Epidermal growth factor receptor intron 1 (CA) n dinucleotide repeat polymorphism and mutations associated with the responsiveness of molecular targeted therapy in lung cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e14595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14595 Background: To explore EGFR gene intron 1 (CA)n repeat polymorphism and mutations associated with the responsiveness of molecular targeted therapy in lung cancer. Methods: Both observed groups consisted of 116 somatic specimens of lung cancer and controls consisted of 20 peripheral blood samples were analyzed by direct DNA sequencing of EGFR mutations at exons 18,19,21. Also (CA)n repeat polymorphisms in intron 1 of EGFR from 48 specimens were analyzed. 45 lung cancer patients were followed up. Results: EGFR mutations were found in 24 of 116 somatic specimens (20.69%). Response rate and disease control rate to EGFR TKIs was significantly higher in the patients with EGFR mutations (62.5% vs. 0)(P<0.0l),(100% vs.44.4%) (P<0.05)respectively than those without it in observed groups.In patients harboring EGFR mutations, disease control rate to patients treated with Iressa (100%) was significantly higher than those who never treated with it (40%)(P<0.05). The frequency distribution of EGFR intron 1 (CA)n repeat in 48 specimens was 23(47.9%)low (CA)n repeat(CA≤16)and 25 (52.1%) high repeat(CA>16). There was no significant difference in response rate and disease control rate of EGFR TKIs treatment between low and high (CA)n repeat numbers both in 16 patients with mutations and 18 patients without mutations in observed groups(P>0.05). Conclusions: Somatic mutations of EGFR is a major determinant of EGFR TKIs response in lung cancer. There was no significant difference in response rate and disease control rate of EGFR TKIs treatment between low (CA) n repeat patients and high repeat ones under the consideration of the mutant factor. No significant financial relationships to disclose.
Collapse
|
84
|
Lai R, Feng L, Liu L, Xie L, Wu X, Zhang S, Tang X, Geng J, Chen T. The clinical pathogensis significance associated with mutation of APC MCR in colorectal neoplasms. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15119 Background: To explore the clinical pathogensis evalution of codon 1493,1367 and 1328 mutations in MCR (mutation cluster region) of exon 15 of APC (Adenomatous polyposis coli) gene in cases of colorectal neoplasm and the family history. Methods: The specimens from 21 colorectal adenoma specimens groups,16 colorectal carcinoma groups, 20 healthy germline groups with positive familial history and 8 healthy germline groups without familial history. MCR of APC gene were extracted and specificly amplified, then sequenced by sequencer, the codon mutations were analyzed between the 4 groups and various genotypes tested with Chi-square. Results: The codon mutations were three variations: 1493(ACG > ACA), 63/69(91.3%); 1367(CAG > TAG), 1/69(1.4%) and 1328(CAG>TAG), 5/69(7.2%). The allele mutations were checked out four genotypes such as 4478(G→A), 41/69(59.4%); 4478(G/A), 22/69(31.9%); 4096(C/T), 1/69 (1.4%) and 3979(C/T), 5/69(7.2%); but the significant groups status (P<0.05) were shown between the adenoma and nonfamily history group on the analysis of 4478(G→A) and (G/A), also the significant differences were tested between the with and without family history on the analysis of 4478(G→A). The significant differences (P<0.05) in pathogensis mutant phenotypes were involved between 4478(G→A) with 4478(G/A), 4096(C/T) and 3979(C/T), respectively; also showed between 4478(G/A) with 4096(C/T) and 3979(C/T); but not between 4096(C/T) and 3979(C/T) (P>0.05). Conclusions: In our data, the highest mutant frequency 4478(G→A) of 1493(ACG>ACA) presented to the significant phenotype of positive history and adenoma, but 4478 (G/A) were associated with colorectal adenocancer, which was discovered in the different effect to candidators despite the same synonymous mutation. In researches, APC MCR codon 1367 and 1328 genotyping were significantly presented in the colorectal cancergenetic phenotypes in somatic cells only. No significant financial relationships to disclose.
Collapse
|
85
|
Xie L, Lai R, Wu X, Zhang S, Tang X, Chen T. Correlation between K-ras mutations status and benefit from cetuximab treatment in advanced colorectal cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15084 Background: Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We follow -up study the efficacy and toxicity of cetuximab with chemotherapy in the treatment of advanced colorectal cancer from Chinese in East China. Methods: We analyzed tumor samples from 120 patients with advanced colorectal cancer by direct sequencing, to observe the mutations status in exon 2,3 of K-ras gene. And 30 patients were followed up according the RECIST standard for their treatment outcome of cetuximab plus chemotherapy at 2 -12 months. Results: K-ras mutations were identified in 48 of 120(40%) patients with colorectal cancer in exon2, which including 8 mutation types; 38/48(79.2%) mutations in 12 codon(G12D 43.7%,G12V 25%,G12C 10.4%,G12R 6%,G12S 4%,G12A 2%) and 10/48(18.7%) in 13 codon(G13D 18.7%,G13C 2%). None mutation was found in 61codon of exon3. we observed the clinical efficacy of 30 patients treated by cetuximab plus chemotherapy, of 21 patients with wild-type K-ras tumors as compared with 9 patients with mutated K-ras significantly improved the response rate (5/21 21.8% vs 1/9 11.1%,P<0.01)and the disease control rate (19/21 90.4% vs,2/9 22.2%,P<0.01). There were a few patients with mutated K-ras tumors benefit from cetuximab, in which the fluorescence intensity of mutation cells of all detected tumor tissue approach to 1:3 status by sequencing analysis. The major toxicities of treatment were acne-like rash, which were found in 14/21(66.6%)of patients with wild-type K- ras, and 5/9(55.5%)of patients with mutated K-ras . Conclusions: The East-China patients share the same (40%) mutation frequency and type of k-ras gene with other races . Patients with wild type K-ras mutation have significantly higher Response rate and disease control rate on cetuximab plus chemotherapy treatment .Our results once again show that somatic mutations status of k-ras is a major determinant of cetuximab response in advanced colorectal cancer. There was no statistical correlation between acne-like rash of the major toxicities and mutations status of k-ras. There were a few patients bearing mutated k-ras did benefit from cetuximab, that would need to be validation between Chinese or Ethnicity association phenotype by a large numbers of samples. No significant financial relationships to disclose.
Collapse
|
86
|
Yang SY, Liu H, Liu R, Zhang KY, Lai R. Saccharibacillus kuerlensis sp. nov., isolated from a desert soil. Int J Syst Evol Microbiol 2009; 59:953-7. [DOI: 10.1099/ijs.0.005199-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
87
|
Zhou Y, Wei W, Wang X, Lai R. Proposal of Sinomonas flava gen. nov., sp. nov., and description of Sinomonas atrocyanea comb. nov. to accommodate Arthrobacter atrocyaneus. Int J Syst Evol Microbiol 2009; 59:259-63. [DOI: 10.1099/ijs.0.000695-0] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
88
|
Bard JD, Gelebart P, Amin HM, Young LC, Ma Y, Lai R. Signal transducer and activator of transcription 3 is a transcriptional factor regulating the gene expression of SALL4. FASEB J 2009; 23:1405-14. [PMID: 19151334 DOI: 10.1096/fj.08-117721] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Both signal transducer and activator of transcription 3 (STAT3) and SALL4 are important in maintaining the pluripotent and self-renewal state of embryonic stem cells. We hypothesized that STAT3, a latent transcriptional factor, may regulate the gene expression of SALL4. In support of this hypothesis, DNA sequence analysis of the SALL4 gene promoter revealed four putative STAT3-binding sites. Using a SALL4-luciferase reporter gene assay, we found that modulation of the STAT3 activity significantly up-regulated the luciferase activity. By chromatin immunoprecipitation, the segment of the SALL4 promoter showing the highest affinity to STAT3 was localized to -366 to -163, in which there was only one putative STAT3 binding site starting at -199. Site-directed mutagenesis of all four putative STAT3-binding sites in the SALL4 promoter significantly reduced its responsiveness to STAT3, although the most dramatic effect was seen at the binding site starting at -199. We further tested the functional relationship between STAT3 and SALL4 using MDA-MB-231, a breast cell line carrying constitutive SALL4 expression and STAT3 activity. Down-regulation of the STAT3 activity using a dominant-negative construct resulted in a significant decrease in the expression of SALL4. To conclude, our data suggest that STAT3 and SALL4 probably cooperate in both physiological and pathological states.
Collapse
|
89
|
Wei W, Zhou Y, Wang X, Huang X, Lai R. Sphingobacterium anhuiense sp. nov., isolated from forest soil. Int J Syst Evol Microbiol 2008; 58:2098-101. [DOI: 10.1099/ijs.0.65864-0] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
90
|
Liu R, Liu H, Zhang CX, Yang SY, Liu XH, Zhang KY, Lai R. Sphingobacterium siyangense sp. nov., isolated from farm soil. Int J Syst Evol Microbiol 2008; 58:1458-62. [DOI: 10.1099/ijs.0.65696-0] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
91
|
Liu R, Liu H, Feng H, Wang X, Zhang CX, Zhang KY, Lai R. Pseudomonas duriflava sp. nov., isolated from a desert soil. Int J Syst Evol Microbiol 2008; 58:1404-8. [DOI: 10.1099/ijs.0.65716-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
92
|
Reiman T, Seve P, Vataire A, Dunant A, Rosell R, Graziano S, Seymour L, Pirker R, Lai R. Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): A validation study on three randomized trials. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7506] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
93
|
Hsi E, Jung S, Lai R, Johnson J, Cook J, Jones D, DeVos S, Cheson BD, Damon LE, Said J. Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
94
|
Santini D, Perrone G, Vincenzi B, Lai R, Cass C, Alloni R, Rabitti C, Antinori A, Vecchio F, Morini S, Magistrelli P, Coppola R, Mackey JR, Tonini G. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann Oncol 2008; 19:724-8. [PMID: 18187485 DOI: 10.1093/annonc/mdm576] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Gemcitabine is an acceptable alternative to best supportive care in the treatment of advanced biliary tract cancers. The human equilibrative nucleoside transporter 1 (hENT1) is a ubiquitous protein and is the major means by which gemcitabine enters human cells. Moreover, recent reports indicate a significant correlation between immunohistochemical variations of hENT1 in tumor samples and survival after gemcitabine therapy in patients with solid tumors. MATERIALS AND METHODS We used immunohistochemistry to assess the abundance and distribution of hENT1 in tumor samples from radically resected cancer of the ampulla, and sought correlations between immunohistochemical results and clinical parameters including disease outcomes. RESULTS In the 41 individual tumors studied, 12 (29.3%) had uniformly high hENT1 immunostaining. Statistical analysis showed a significant correlation between hENT1 and Ki-67 (P = 0.04). No statistical significant differences were found between immunohistochemical findings and patient characteristics (sex, age, and tumor-node-metastasis). On univariate analysis, hENT1 and Ki-67 expression were associated with overall survival (OS). Specifically, those patients with overexpression of hENT1 showed a shorter OS (P = 0.022) and those with high Ki-67 staining showed a shorter survival (P = 0.05). CONCLUSIONS hENT1 expression is a molecular prognostic marker for patients with resected ampullary cancer and holds promise as a predictive factor to assist in chemotherapy decisions.
Collapse
|
95
|
Zhou Y, Zhang YQ, Zhi XY, Wang X, Dong J, Chen Y, Lai R, Li WJ. Description of Sinobacter flavus gen. nov., sp. nov., and proposal of Sinobacteraceae fam. nov. Int J Syst Evol Microbiol 2008; 58:184-9. [DOI: 10.1099/ijs.0.65244-0] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
96
|
Wheeler L, Lai R, Woldemussie E, Hare WA. Neuroprotection: new pharmacological targets. Eye (Lond) 2007. [DOI: 10.1038/sj.eye.6702889] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
97
|
Amin HM, Hoshino K, Yang H, Lin Q, Lai R, Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J Pathol 2007; 212:402-10. [PMID: 17503411 DOI: 10.1002/path.2178] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Chronic myeloid leukaemia (CML) is characterized by t(9;22)(q34;q11) and the aberrant expression of the fusion protein Bcr-Abl that leads to constitutive activation of c-Abl kinase. Bcr-Abl plays a major role in the development and progression of CML through chronic, accelerated, and blast phases. The interaction between Bcr-Abl and other oncogenic molecules has been extensively documented. Nonetheless, negative regulatory mechanisms of Bcr-Abl are not completely defined. One major inhibitory pathway is mediated via the SH2 domain-containing protein tyrosine phosphatase Shp1. In the present study, we demonstrate that Shp1 levels are markedly decreased in advanced stage CML patients compared with those in chronic phase. This process was independent of DNA methylation. Furthermore, we did not detect mutations in the Shp1 gene in CML cell lines or patient samples. These data suggest that the decrease in Shp1 in advanced stage CML patients is due to post-transcriptional modifications. Our findings suggest that the decrease in Shp1 expression levels plays a role in the progression of CML. Also, the decrease in Shp1 and subsequently its inhibitory effect on Bcr-Abl could provide an explanation for imatinib resistance seen in advanced stage CML patients.
Collapse
MESH Headings
- Adult
- Aged
- DNA Methylation
- DNA Mutational Analysis/methods
- DNA, Complementary/genetics
- DNA, Neoplasm/genetics
- Disease Progression
- Female
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Male
- Middle Aged
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- Protein Phosphatase 1
- Protein Tyrosine Phosphatase, Non-Receptor Type 6/genetics
- Protein Tyrosine Phosphatase, Non-Receptor Type 6/metabolism
- RNA, Messenger/genetics
- RNA, Neoplasm/genetics
- Reverse Transcriptase Polymerase Chain Reaction/methods
Collapse
|
98
|
Stone S, Cooper B, Kibbler C, Cookson B, Robert J, Medley G, Duckworth G, Lai R, Ebrahim S, Brown E, Wiffen P, Davey P. The ORION statement: a CONSORT equivalent for infection control studies- Guidelines for transparent reporting of Outbreak Reports and Intervention studies Of Nosocomial infection. J Infect 2007. [DOI: 10.1016/j.jinf.2007.04.136] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
99
|
Han R, Lai R, Ding Q, Wang Z, Luo X, Zhang Y, Cui G, He J, Liu W, Chen Y. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 2007; 50:1960-1968. [PMID: 17639303 DOI: 10.1007/s00125-007-0752-7] [Citation(s) in RCA: 98] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2007] [Accepted: 05/31/2007] [Indexed: 01/05/2023]
Abstract
AIMS/HYPOTHESIS In humans, one of the hallmarks of type 2 diabetes is a reduced plasma concentration of HDL and its major protein component, apolipoprotein A-I (APOA-I). However, it is unknown whether APOA-I directly protects against diabetes. The aim of this study was to characterise the functional role of APOA-I in glucose homeostasis. METHODS The effects of APOA-I on phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-coenzyme A carboxylase (ACC), glucose uptake and endocytosis were analysed in C2C12 myocytes. Glucose metabolism was investigated in Apoa-I knockout (Apoa-I (-/-)) mice. RESULTS APOA-I was able to stimulate the phosphorylation of AMPK and ACC, and elevated glucose uptake in C2C12 myocytes. APOA-I could be endocytosed into C2C12 myotubes through a clathrin-dependent endocytotic process. Inhibition of endocytosis abrogated APOA-I-stimulated AMPK phosphorylation. In Apoa-I (-/-) mice, AMPK phosphorylation was reduced in skeletal muscle and liver, and expression of gluconeogenic enzymes was increased in liver. In addition, the Apoa-I (-/-) mice had increased fat content and compromised glucose tolerance. CONCLUSIONS/INTERPRETATION Our data indicate that APOA-I has a protective effect against diabetes via activation of AMPK. ApoA-I deletion in the mouse led to increased fat mass and impaired glucose tolerance.
Collapse
|
100
|
Chu YW, Cheung TKM, Tung V, Tiu F, Lo J, Lam R, Lai R, Wong KK. A blood isolate of Neisseria meningitidis showing reduced susceptibility to quinolones in Hong Kong. Int J Antimicrob Agents 2007; 30:94-5. [PMID: 17408928 DOI: 10.1016/j.ijantimicag.2006.11.028] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2006] [Accepted: 11/23/2006] [Indexed: 10/23/2022]
|